BlossomHill Therapeutics IPO: $16 pricing on 2026-08-06
BlossomHill Therapeutics priced 9,375,000 shares at $16 in its dated 2026-08-06 announcement, with approximately $150.0 million base gross proceeds.
Dated offering terms — 2026-08-06
BlossomHill Therapeutics announced a price of $16 for 9,375,000 shares, representing about $150.0 million before fees. Its announcement expected Nasdaq Global Select Market trading under BLSM on 7 August 2026.
BlossomHill develops small-molecule cancer medicines using a chemistry-based approach. Its upsized offering excluded a potential 1,406,250 additional shares from the stated base proceeds. The option and base offering should be tracked separately.
What the financing changes
The analytical focus is whether the funded compounds can demonstrate a clinically useful balance of activity and tolerability. Fundraising is an input into that process, rather than evidence of its outcome. Readers comparing oncology offerings should connect available resources to the number, size and duration of the planned studies. A portfolio can offer more than one route to success, but each route needs capital. Later disclosures should therefore explain how program selection and trial spending change over time.
The trading timetable above records the issuer's expectations at pricing; it is not a live market-price quotation.